Considering a healthy pipeline of niche products and superior execution in thebranded generics segment, we value Cipla on SOTP basis (24x 12M forwardearnings and NPV of INR30 for g-Revlimid) to arrive at our TP of INR1,700. Wemaintain BUY rating on the stock.